drugset
drugset / Trial / NCT01750853

A Study of LY3045697 in Healthy Participants

NCT01750853 ↗

Phase 1 Completed 27 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of LY3045697 after a single dose, and to determine how long LY3045697 remains in the body. Two cohorts (groups) of 9 participants each will participate in 3 dosing periods. These participants will receive placebo in one period only. A third cohort of 9 will participate in 2 dosing periods and participants will receive either 2 dose levels of LY3045697 or 1 dose level of LY3045697 and placebo by the end of both periods.

Timeline

Start
2013-01
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3045697 Unknown 0.1 mg Oral
Subject LY3045697 Unknown 0.3 mg Oral
Subject LY3045697 Unknown 1 mg Oral
Subject LY3045697 Unknown 3 mg Oral
Subject LY3045697 Unknown 10 mg Oral
Subject LY3045697 Unknown 30 mg Oral
Subject LY3045697 Unknown 100 mg Oral
Subject LY3045697 Unknown 300 mg Oral

Indications

No indication recorded.